Evidence map›Paper›PMID 24512192›Full record

ReviewAntioxidants & redox signaling2015

NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Becky A Diebold, Susan M E Smith, Yang Li, J David Lambeth

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antioxidants & redox signaling, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Becky A Diebold1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, Georgia.
Susan M E Smith2 Department of Biology and Physics, Kennesaw State University , Kennesaw, Georgia.
Yang Li1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, Georgia.
J David Lambeth1 Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, Georgia.
Emory University · USKennesaw State University · US

Funding

Regulation of Nox Enzymes by Calcium and Novel SubunitsR01CA105116 · NCI · EMORY UNIVERSITY · PI LAMBETH, JOHN DAVID · 2004 to 2014
$2.4M
NOX1 and NOX2 as Therapeutic Targets in InfluenzaR33AI102197 · NIAID · EMORY UNIVERSITY · PI LAMBETH, JOHN DAVID · 2014 to 2016
$1.4M
NCI NIH HHS R01 CA105116NIAID NIH HHS R33 AI102197
6 · The paper itself

Abstract

significanceNOX2 is important for host defense, and yet is implicated in a large number of diseases in which inflammation plays a role in pathogenesis. These include acute and chronic lung inflammatory diseases, stroke, traumatic brain injury, and neurodegenerative diseases, including Alzheimer's and Parkinson's Diseases. RECENT ADVANCES: Recent drug development programs have targeted several NOX isoforms that are implicated in a variety of diseases. The focus has been primarily on NOX4 and NOX1 rather than on NOX2, due, in part, to concerns about possible immunosuppressive side effects. Nevertheless, NOX2 clearly contributes to the pathogenesis of many inflammatory diseases, and its inhibition is predicted to provide a novel therapeutic approach. CRITICAL ISSUES: Possible side effects that might arise from targeting NOX2 are discussed, including the possibility that such inhibition will contribute to increased infections and/or autoimmune disorders. The state of the field with regard to existing NOX2 inhibitors and targeted development of novel inhibitors is also summarized. FUTURE DIRECTIONS: NOX2 inhibitors show particular promise for the treatment of inflammatory diseases, both acute and chronic. Theoretical side effects include pro-inflammatory and autoimmune complications and should be considered in any therapeutic program, but in our opinion, available data do not indicate that they are sufficiently likely to eliminate NOX2 as a drug target, particularly when weighed against the seriousness of many NOX2-related indications. Model studies demonstrating efficacy with minimal side effects are needed to encourage future development of NOX2 inhibitors as therapeutic agents.

Indexed as

Drug DiscoveryAnimalsEnzyme InhibitorsHumansInflammationMembrane GlycoproteinsNADPH Oxidase 2NADPH OxidasesCYBB protein, humanEnzyme InhibitorsMembrane GlycoproteinsNADPH Oxidase 2NADPH Oxidases

Identifiers

PMID24512192
PMCPMC4545678
OpenAlexW1495021455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.